Advanced Research & Development: PMT 1

New Product

  • Hardware
    • Smaller housing, lighter materials
    • Co-processor improvement
    • Electrical conduit material modified
    • Increased device sensitivity
    • User feedback
  • Software/Firmware
    • Additional algorithms (waveform) broadening diagnoses treated
    • New diagnoses offered in new, diagnosis-specific devices
    • Cloud based data collection and analytical system

For more information please contact:

Conrad F. Mir
President, CEO and Director
Calmare Therapeutics Incorporated
This email address is protected. Javascript must be enabled to view it.
Tel: 203.368.6044